Arrowstreet Capital Limited Partnership Has $150.28 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Arrowstreet Capital Limited Partnership boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 194,695 shares of the biopharmaceutical company’s stock after purchasing an additional 2,111 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Regeneron Pharmaceuticals were worth $150,279,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Ellerson Group Inc. ADV increased its position in shares of Regeneron Pharmaceuticals by 49.2% during the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock worth $4,556,000 after acquiring an additional 2,671 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Regeneron Pharmaceuticals by 118.1% during the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after acquiring an additional 74,350 shares in the last quarter. TD Asset Management Inc increased its position in shares of Regeneron Pharmaceuticals by 15.9% during the third quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock worth $210,437,000 after acquiring an additional 51,407 shares in the last quarter. Stevens Capital Management LP bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $792,000. Finally, PNC Financial Services Group Inc. grew its position in Regeneron Pharmaceuticals by 17.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 17,316 shares of the biopharmaceutical company’s stock worth $9,736,000 after purchasing an additional 2,601 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $614.98 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals, Inc. has a one year low of $503.25 and a one year high of $821.11. The company’s fifty day moving average price is $689.17 and its 200-day moving average price is $736.78. The firm has a market capitalization of $65.02 billion, a price-to-earnings ratio of 14.98, a PEG ratio of 1.34 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $8.22 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Analyst Ratings Changes

A number of brokerages have issued reports on REGN. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.